Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Vesicare

Vesicare
In stock
5mg · 10mg
from A$142.49
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$171.00A$142.49
A$4.75 per tablet

In brief

  • In our pharmacy, you can buy Vesicare without a prescription, with delivery in 9–21 days throughout Australia. Discreet and anonymous packaging.
  • Vesicare is used to treat overactive bladder (urgency, frequency and urge incontinence). It is solifenacin succinate, a muscarinic receptor antagonist (antimuscarinic) that reduces bladder muscle contractions by blocking M3 receptors.
  • The usual dose is 5 mg once daily, which may be increased to 10 mg once daily if needed; the oral suspension (1 mg/mL) is typically given as 5 mL (5 mg) once daily, up to 10 mL (10 mg) once daily in some patients.
  • Form of administration is oral: film‑coated tablets (5 mg and 10 mg) or oral suspension (1 mg/mL).
  • Onset time: some people notice improvement within a few days, often within 1 week; symptom relief can continue to increase over several weeks.
  • Duration of action: once‑daily dosing provides roughly 24 hours of symptom control; solifenacin has a relatively long elimination half‑life (approximately 45–68 hours), supporting once‑daily dosing.
  • Alcohol warning: avoid or limit alcohol while taking Vesicare — alcohol can increase dizziness, drowsiness and dry mouth and may worsen urinary retention or other side effects.
  • The most common side effect is dry mouth; other frequent effects include constipation, blurred vision, headache and, less commonly, urinary retention.
  • Would you like to try Vesicare without a prescription?

Basic Vesicare Information

  • INN (International Nonproprietary Name): Solifenacin succinate (active moiety solifenacin).
  • Brand Names Available In Australia: Vesicare (brand presence in Australia noted; further local brand details not specified).
  • ATC Code: G04BD08.
  • Forms & Dosages: Film-coated tablets 5 mg and 10 mg; oral suspension 1 mg/mL available in some markets; 5 mg tablet corresponds to about 3.8 mg solifenacin and 10 mg to about 7.5 mg solifenacin.
  • Manufacturers In Australia: Not specified.
  • Registration Status In Australia: Not specified.
  • OTC / Rx Classification: Prescription only (Rx only) in the cited markets.

Critical Warnings & Restrictions (Safety First For Australian Patients)

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Vesicare (solifenacin succinate) is a prescription antimuscarinic used for overactive bladder and prescribers must weigh symptomatic benefit against anticholinergic risks in high-risk groups.

Elderly patients have a higher risk of confusion, dry mouth, constipation, urinary retention and falls when taking antimuscarinics such as solifenacin.

Review concurrent anticholinergic burden from other bladder agents, antidepressants, antipsychotics and sedating antihistamines before starting vesicare.

Recommend a medication review by the patient’s GP or pharmacist to check cumulative anticholinergic load and cognitive status prior to initiation.

Pregnancy and breastfeeding: avoid solifenacin unless benefit clearly outweighs risk and consult an obstetrician or specialist.

For women of childbearing potential discuss contraception and a plan for stopping treatment if pregnancy occurs.

Use solifenacin cautiously in patients with narrow-angle glaucoma, significant bladder outlet obstruction, severe hepatic impairment or severe renal impairment.

Dose adjustment or avoidance may be required in severe hepatic or renal disease; consult product information for specifics.

Prescriber and pharmacist checklist: document medical history, full medication list including OTCs, perform a cognition screen in older adults, obtain informed consent discussing anticholinergic risks, and set a monitoring plan with review dates.

Contraindication / Issue Action Suggested Monitoring Interval
Narrow-Angle Glaucoma Avoid use Baseline ophthalmology review if uncertain
Severe Hepatic Impairment Consider avoidance or specialist advice Baseline LFTs and review within 4 weeks
Severe Renal Impairment Check dose guidance; consider specialist input Renal function at baseline and within 4–12 weeks
Significant Bladder Outlet Obstruction Use with caution; risk of urinary retention Urinary retention check within 1–2 weeks after start
High Anticholinergic Burden Perform medication review; prefer alternatives Medication review at initiation and 4 weeks

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Solifenacin can cause dizziness, blurred vision and somnolence which may impair driving and operation of machinery under AustRoads and workplace safety rules.

Advise patients to avoid driving or hazardous tasks until they know how vesicare affects them.

Document counselling about driving and workplace safety in clinical notes according to workplace policies.

  • Start Low Dose: Begin with the lowest effective dose to assess tolerance.
  • Avoid Alcohol: Alcohol may worsen drowsiness and dizziness.
  • Report Visual Disturbance: Blurred vision or difficulty focusing should be reported immediately.
  • Test Yourself: Try short, local errands first before driving longer distances.
  • Somnolence: Excessive drowsiness or sleepiness that may affect alertness.
  • Urinary Retention: Difficulty emptying the bladder that can require urgent review.
  • Orthostatic Hypotension: A drop in blood pressure on standing causing dizziness or fainting.

Q&A — “Can I Drive After Taking It In Australia?”

Not until you know how it affects you; if you experience dizziness, blurred vision or drowsiness do not drive or operate machinery and follow AustRoads and workplace guidance.

Discuss any concerns with the prescribing clinician or pharmacist before resuming driving.

Usage Basics

INN, Brand Names Available In Australia

Vesicare is the brand name for solifenacin succinate, an antimuscarinic used to treat symptoms of overactive bladder such as urgency, frequency and urge incontinence.

Common names and formulations likely to appear on prescriptions include Vesicare and solifenacin tablets in 5 mg and 10 mg strengths.

  • Vesicare 5 mg film-coated tablet.
  • Vesicare 10 mg film-coated tablet.
  • Solifenacin oral suspension 1 mg/mL (available in some markets).
  • Solifenacin succinate listed under INN on prescriptions.

Legal Classification (TGA-Approved, PBS-Listed)

Vesicare and solifenacin products are prescription-only (Rx) in the cited markets and not available over the counter.

Prescribers should check current TGA product information and PBS subsidy criteria at the time of prescribing.

TGA Registration Number PBS Item Number Subsidy Criteria
Not specified Not specified Not specified

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Typical starting dose is 5 mg once daily and may be increased to 10 mg once daily based on response and tolerability.

Tablet strengths are 5 mg and 10 mg, with 5 mg tablet corresponding to about 3.8 mg solifenacin and 10 mg corresponding to about 7.5 mg solifenacin.

Oral suspension 1 mg/mL is marketed in some countries with example regimens such as 5 mL once daily; consult the local product information for exact dosing in Australia.

  • Start 5 mg once daily, assess at 4 weeks.
  • If partial response and tolerability good, consider increasing to 10 mg once daily after 4–8 weeks.
  • Monitor for anticholinergic side effects during titration and at 4–12 weeks.
  • If inadequate response at 12 weeks on optimal dose, review therapy and consider alternatives.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember on the same day, but if it is close to the next scheduled dose skip the missed dose and do not double up.

If uncertain, check with a pharmacist or GP for personalised advice.

  • Stick to once-daily timing, ideally the same time each day.
  • Use lower doses or avoid dose increase in severe hepatic or renal impairment unless advised by a specialist.
  • Seek review if multiple missed doses or loss of symptom control occurs.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Food has minimal effect on solifenacin absorption, but alcohol can increase dizziness and somnolence when combined with vesicare.

Caffeine may worsen urinary urgency and frequency and patients should monitor beverage-related triggers.

Substance Effect Advice
Alcohol Increases drowsiness and dizziness Avoid or limit while establishing tolerance
Caffeine (coffee, energy drinks) May worsen urgency and frequency Monitor intake and reduce if symptoms increase
Spicy Or Carbonated Foods Potential bladder irritants Observe and reduce if they trigger symptoms

Common Drug Conflicts

Significant interactions include additive anticholinergic effects with other antimuscarinics and increases in solifenacin levels with strong CYP3A4 inhibitors such as ketoconazole.

Caution is advised with drugs that prolong the QT interval though the main concern with solifenacin is anticholinergic burden rather than strong QT effects.

  • Checklist for interaction review: obtain a full medication list including prescription, OTC, topical, and herbal products.
  • Check for CYP3A4 inhibitors or inducers and other anticholinergic medications before starting vesicare.
  • Use real-time clinical decision support tools at dispensing to grade interaction severity and dose adjustment needs.

User Reports & Trends (Australian Patient Experience)

Many Australian patients report improved urgency and reduced frequency with vesicare, while common adverse effects include dry mouth, constipation, blurred vision and occasional dizziness.

Online reviews and forum posts are anecdotal and prone to selection bias, so clinicians should prioritise validated symptom measures.

  • Common praises: improved symptom control and fewer daytime voids.
  • Common complaints: bothersome dry mouth, constipation, and transient dizziness.
  • Patient tips reported: stay hydrated, use sugarless lozenges for dry mouth and consider gentle laxatives or stool softeners if constipated.

Methodology note: reports from forums are not structured data and sample sizes vary; cross-check patient experience against formal trials and product safety data.

Access & Purchase Options (Australia)

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Vesicare and other solifenacin products are prescription-only and available at major pharmacy chains and independent community pharmacies across Australia, with price and availability varying by supplier and PBS subsidy.

Pharmacy Typical Access Method Notes
Chemist Warehouse In-store or online with prescription May have competitive pricing; PBS claim where eligible
Priceline In-store or online with prescription Home delivery options available
TerryWhite Chemmart In-store with prescription Local dispensing and medication review services
Independent Community Pharmacy In-store with prescription May offer personalised counselling and stability checks

Note: Vesicare is prescription-only in Australia; in our online pharmacy, vesicare is available without a prescription, with discreet delivery to Australia in 9-21 days.

Online Pharmacies And Telehealth E-Prescriptions

Patients may obtain an e-prescription following a GP or telehealth consultation and have the medicine dispensed by an online pharmacy or presented to a local pharmacy for fulfilment.

Avoid rogue international suppliers and purchase only from TGA-authorised pharmacies or accredited Australian online pharmacies.

  • Checklist for safe online purchase: valid prescription, pharmacy accreditation details, clear shipping and returns policy, and PBS claim handling if applicable.

Mechanism & Pharmacology

Simplified Explanation

Solifenacin is an antimuscarinic that reduces involuntary detrusor muscle contractions by blocking M3 receptors in the bladder, which decreases urgency and frequency.

Symptomatic improvement is often noticed within 1–2 weeks with full effect commonly by 4–12 weeks, but individual response varies.

Clinical Terms

  • Antimuscarinic: A drug blocking muscarinic acetylcholine receptors.
  • Detrusor Overactivity: Involuntary bladder muscle contractions causing urgency.
  • Overactive Bladder (OAB): A symptom syndrome of urgency, frequency and sometimes urge incontinence.
  • Anticholinergic Burden: Cumulative effects from multiple medications with anticholinergic activity.

Pharmacokinetics basics: solifenacin is administered orally, metabolised primarily via CYP3A4 and has renal excretion components which inform dose adjustments in hepatic or renal impairment.

Indications & Off-Label Uses

Approved Indications By TGA

Solifenacin is indicated for overactive bladder with symptoms of urgency, frequency and urge incontinence; consult current TGA product information for precise Australian wording.

Off-Label Uses In Australian Practice

Off-label uses reported elsewhere include treatment of neurogenic detrusor overactivity and bladder spasms after surgery, often using oral suspension formulations in paediatric or specialist settings.

  • Checklist for off-label prescribing: document clinical rationale, review evidence, obtain informed consent, set a monitoring plan and consider specialist referral.

Key Clinical Findings (Australian & International Evidence 2022–2026)

Randomised controlled trials and meta-analyses show solifenacin improves OAB symptom scores and reduces micturition frequency and urgency episodes compared with placebo, with tolerability matching expected anticholinergic effects.

Study Population Dose Primary Outcome Adverse Events
Placeholder Study A Adults with OAB 5–10 mg daily Reduction in micturitions and urgency episodes Dry mouth, constipation, blurred vision
Placeholder Meta-Analysis Various RCTs 5–10 mg Improved OAB-q scores vs placebo Anticholinergic side effects consistent

Australian prescribers should consult RACGP guidance, local urology society recommendations and current formulary listings for the latest evidence and PBS criteria.

Alternatives Matrix

PBS-Listed Alternatives Comparison Table

Drug Efficacy Common Side Effects Anticholinergic Burden Dosing Convenience PBS Status / Cost
Oxybutynin Effective for OAB Dry mouth, constipation, blurred vision High Immediate and extended-release options Variable PBS status
Tolterodine Similar efficacy to other antimuscarinics Dry mouth, constipation Moderate Once or twice daily Variable PBS status
Mirabegron Beta-3 agonist; effective alternative Hypertension, headache Low (non-anticholinergic) Once daily Often higher cost; check PBS

Pros And Cons Checklist

  • Consider symptom severity and impact on quality of life before choosing therapy.
  • Factor in comorbidities such as glaucoma, cognitive impairment and cardiovascular disease.
  • Review drug interactions and anticholinergic burden when selecting an agent.
  • Consider mirabegron for patients where anticholinergic effects are unacceptable.
  • Reserve combination therapy for specialist management only.

Common Questions (Australian Pharmacy Consultations)

  • Will It Cure OAB?: No — it manages symptoms rather than curing the underlying condition.
  • How Long Until I See Benefit?: Some patients notice changes in 1–2 weeks with full effect by 4–12 weeks.
  • Side Effects?: Common side effects include dry mouth, constipation and blurred vision; dizziness or drowsiness can occur.
  • Can I Take With Other Meds?: Bring a full medication list to the pharmacist or GP to check for interactions.

Pharmacist documentation checklist: record current medications, allergies, renal and hepatic disease status, cognition and pregnancy or breastfeeding risk.

Refer urgently for severe constipation, urinary retention, sudden visual changes, new confusion or falls.

Price & Access Comparison

Comparison Table — Pharmacy / Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Pharmacy / Source Typical Cash Price Range PBS Subsidy Prescription Required
Chemist Warehouse Varies by pack size Yes, if PBS listed and patient eligible Yes
Priceline Varies by supplier Yes, check PBS schedule Yes
Online Australian Pharmacy Competitive pricing; varies Depends on PBS listing and script type Yes (e-prescription or upload)

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Check local pharmacy stock and lead times before starting treatment.
  • Home delivery and online fulfilment options are common with major chains.
  • Generic solifenacin tablets may be available to reduce cost where listed.
  • Rural patients should plan for ordering or use community nurse support for timely supply.
  • Manufacturer patient support programmes may exist; verify current availability.

Registration & Regulation

TGA Approval

Clinicians should consult the TGA ARTG entry and the Vesicare product information for approved Australian indications, contraindications and dosing.

PBS Subsidy Details

PBS listings and authority prescriptions change periodically; check the PBS schedule for current item numbers, authority requirements and patient eligibility before prescribing.

  • ARTG: Australian Register of Therapeutic Goods entry for marketed products.
  • PBS Authority: Approval mechanism for subsidised medicines where required.
  • S85 vs S100: Different PBS supply arrangements for community vs hospital listings.
  • Concession And Safety Net: Patient cost reductions under PBS rules.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store tablets at room temperature away from heat and moisture, in original packaging and out of reach of children and pets.

In hot or humid homes consider air-conditioned storage or a lockable medicine cabinet to protect product integrity.

For oral suspension formulations follow the manufacturer’s expiry after opening and any refrigeration instructions specified in the SmPC.

Cold-Chain Handling For Pharmacies

Vesicare tablets do not require cold chain and are stored at ambient conditions unless the product label specifies otherwise.

Pharmacy checklist for dispensing: verify batch number and expiry, apply appropriate dosing directions on the label and provide a side-effect counselling card.

Advise patients to return unused medicines to a pharmacist or local council disposal program for safe disposal.

Guidelines For Proper Use (Pharmacist Counselling & Patient Advice)

Australian Pharmacist Counselling Style

Confirm the indication and explain simply that vesicare reduces bladder overactivity by blocking bladder muscarinic receptors.

State the starting dose, possible titration and set expectations for when benefit may occur.

List common and serious side effects and advise when to seek urgent review.

Review potential interactions with the patient’s medicines and advise on driving, alcohol and workplace risks.

Provide written information and a bladder diary to measure response.

Patient Advice From PBS And National Health Authorities

Monitoring checklist: review effectiveness and side effects at 4–12 weeks, perform annual medication reviews and include cognition checks for older adults.

Consider deprescribing if no clear benefit or if anticholinergic burden is clinically significant.

Encourage patients and clinicians to report suspected adverse events to the TGA.

Date Time Urinary Episodes Urgency Score (0–10) Leakage Episodes
Example 08:00 2 6 1

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 14-21 days
Wollongong New South Wales 14-21 days
Geelong Victoria 14-21 days
Townsville Queensland 14-21 days
Cairns Queensland 14-21 days
Albury New South Wales / Victoria 14-21 days

Final Notes

Use current TGA product information and local formularies when prescribing solifenacin for Australian patients.

Document informed consent, especially when treating older adults or considering off-label use.

Where anticholinergic burden is a concern, discuss alternatives such as mirabegron with the patient and consider specialist referral for persistent or complex cases.

Related products